Prometheus Biosciences, Inc is a biotechnology business based in the US. Prometheus Biosciences shares (RXDX) are listed on the NASDAQ and all prices are listed in US Dollars. Prometheus Biosciences employs 33 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Prometheus Biosciences
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RXDX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Prometheus Biosciences stock price (NASDAQ: RXDX)Use our graph to track the performance of RXDX stocks over time.
Prometheus Biosciences shares at a glance
|52-week range||$16.11 - $30.64|
|50-day moving average||$23.61|
|200-day moving average||$22.32|
|Wall St. target price||$32.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Prometheus Biosciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Prometheus Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Prometheus Biosciences financials
|Revenue TTM||$1.8 million|
|Gross profit TTM||$-17,918,000|
|Return on assets TTM||-32.93%|
|Return on equity TTM||-176.66%|
|Market capitalisation||$818.9 million|
TTM: trailing 12 months
Shorting Prometheus Biosciences shares
There are currently 939,343 Prometheus Biosciences shares held short by investors – that's known as Prometheus Biosciences's "short interest". This figure is 26.7% up from 741,657 last month.
There are a few different ways that this level of interest in shorting Prometheus Biosciences shares can be evaluated.
Prometheus Biosciences's "short interest ratio" (SIR)
Prometheus Biosciences's "short interest ratio" (SIR) is the quantity of Prometheus Biosciences shares currently shorted divided by the average quantity of Prometheus Biosciences shares traded daily (recently around 267619.08831909). Prometheus Biosciences's SIR currently stands at 3.51. In other words for every 100,000 Prometheus Biosciences shares traded daily on the market, roughly 3510 shares are currently held short.
To gain some more context, you can compare Prometheus Biosciences's short interest ratio against those of similar companies.
However Prometheus Biosciences's short interest can also be evaluated against the total number of Prometheus Biosciences shares, or, against the total number of tradable Prometheus Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prometheus Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Prometheus Biosciences shares in existence, roughly 20 shares are currently held short) or 0.0491% of the tradable shares (for every 100,000 tradable Prometheus Biosciences shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Prometheus Biosciences.
Find out more about how you can short Prometheus Biosciences stock.
Prometheus Biosciences share dividends
We're not expecting Prometheus Biosciences to pay a dividend over the next 12 months.
You may also wish to consider:
- Vedanta (VEDL.US) (67.42% forward annual dividend yield)
Prometheus Biosciences overview
Prometheus Biosciences, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc.
Stocks similar to Prometheus Biosciences
Prometheus Biosciences in the news
Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease
Prometheus to host virtual research and development day
Should I Buy Prometheus Biosciences, Inc. (RXDX)?
Frequently asked questionsWhat percentage of Prometheus Biosciences is owned by insiders or institutions?
Currently 34.845% of Prometheus Biosciences shares are held by insiders and 68.096% by institutions. How many people work for Prometheus Biosciences?
Latest data suggests 33 work at Prometheus Biosciences. When does the fiscal year end for Prometheus Biosciences?
Prometheus Biosciences's fiscal year ends in December. Where is Prometheus Biosciences based?
Prometheus Biosciences's address is: 9410 Carroll Park Drive, San Diego, CA, United States, 92121
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert